xamoterol has been researched along with ketoprofen in 4 studies
| Studies (xamoterol) | Trials (xamoterol) | Recent Studies (post-2010) (xamoterol) | Studies (ketoprofen) | Trials (ketoprofen) | Recent Studies (post-2010) (ketoprofen) |
|---|---|---|---|---|---|
| 269 | 80 | 17 | 3,089 | 677 | 1,008 |
| Protein | Taxonomy | xamoterol (IC50) | ketoprofen (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 6 | Rattus norvegicus (Norway rat) | 0.5 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 1.1942 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 0.008 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 1.168 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 0.18 | |
| Solute carrier family 22 member 6 | Homo sapiens (human) | 1.35 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
4 other study(ies) available for xamoterol and ketoprofen
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |